CN113474348A - 取代的氧代吡啶衍生物 - Google Patents

取代的氧代吡啶衍生物 Download PDF

Info

Publication number
CN113474348A
CN113474348A CN201980091518.1A CN201980091518A CN113474348A CN 113474348 A CN113474348 A CN 113474348A CN 201980091518 A CN201980091518 A CN 201980091518A CN 113474348 A CN113474348 A CN 113474348A
Authority
CN
China
Prior art keywords
methyl
mixture
represents hydrogen
formula
ethyl acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980091518.1A
Other languages
English (en)
Chinese (zh)
Inventor
S·勒里格
S·埃希格
P·埃勒布罗克
S·安劳夫
T·诺伊鲍尔
A·希利施
K·梅耶尔
S·海特迈尔
A·特施特根
M·沙弗尔
J·施坦普富斯
D·郎
王红萍
邹增强
孟祥海
K·M·格里克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of CN113474348A publication Critical patent/CN113474348A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201980091518.1A 2018-12-21 2019-12-18 取代的氧代吡啶衍生物 Pending CN113474348A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/122825 2018-12-21
CN2018122825 2018-12-21
PCT/EP2019/085983 WO2020127504A1 (fr) 2018-12-21 2019-12-18 Dérivés d'oxopyridine substitués

Publications (1)

Publication Number Publication Date
CN113474348A true CN113474348A (zh) 2021-10-01

Family

ID=69143542

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980091518.1A Pending CN113474348A (zh) 2018-12-21 2019-12-18 取代的氧代吡啶衍生物

Country Status (22)

Country Link
EP (1) EP3898633A1 (fr)
JP (1) JP2022514303A (fr)
KR (1) KR20210106504A (fr)
CN (1) CN113474348A (fr)
AR (1) AR117435A1 (fr)
AU (1) AU2019407909B2 (fr)
BR (1) BR112021009435A2 (fr)
CA (1) CA3124220A1 (fr)
CL (1) CL2021001613A1 (fr)
CO (1) CO2021007908A2 (fr)
CR (1) CR20210342A (fr)
DO (1) DOP2021000128A (fr)
EA (1) EA202191764A1 (fr)
EC (1) ECSP21043895A (fr)
IL (1) IL283990A (fr)
JO (1) JOP20210161A1 (fr)
MA (1) MA54521A (fr)
MX (1) MX2021007508A (fr)
PE (1) PE20211790A1 (fr)
SG (1) SG11202104384PA (fr)
TW (1) TW202039510A (fr)
WO (1) WO2020127504A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114560754A (zh) * 2022-02-25 2022-05-31 滁州学院 一种烷基醇的制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11542245B2 (en) * 2018-03-15 2023-01-03 Bayer Pharma Aktiengesellschaft Preparative process
CN114105881B (zh) 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 血小板聚集抑制剂及其制备方法和用途
US20240174633A1 (en) 2021-03-09 2024-05-30 Bayer Aktiengesellschaft Crystalline forms of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
WO2022189280A1 (fr) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates de (4s)-24-chloro-4-éthyl-73-fluoro-35-méthoxy-32,5-dioxo-14-(trifluoro-méthyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
CA3212644A1 (fr) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Formes posologiques pharmaceutiques comprenant du (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2) ,7(1)-dibenzenaheptaphane-74-carboxamide
WO2024223790A1 (fr) * 2023-04-28 2024-10-31 Basf Se Utilisation de 4-alcoxypentanoates d'alkyle comme arômes chimiques
CN116874469B (zh) * 2023-09-06 2023-11-10 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044031A1 (fr) * 2006-07-14 2009-04-08 Bayer HealthCare AG 2-(hétéroaryl)alkylindazole-6-phényl- et -thiénylméthylamide comme inhibiteurs de la thrombine
WO2014154794A1 (fr) * 2013-03-28 2014-10-02 Bayer Pharma Aktiengesellschaft Dérivés de l'oxopyridine substitués et, utilisation desdits dérivés dans le traitement des maladies cardiovasculaires
US20170275282A1 (en) * 2014-09-24 2017-09-28 Bayer Pharma Aktiengesellschaft Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives
US20170283412A1 (en) * 2014-09-24 2017-10-05 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
CN107428689A (zh) * 2015-03-19 2017-12-01 拜耳制药股份公司 作为治疗血栓形成的因子xia抑制剂的氧代吡啶衍生物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
WO2014160592A2 (fr) 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. Inhibiteurs du facteur xia
CA2918814C (fr) 2013-07-23 2021-10-12 Bayer Pharma Aktiengesellschaft Derives de l'oxopyridine substitues et utilisation desdits derives comme facteur xia/plasma
EP3063150B1 (fr) 2013-10-30 2017-11-22 Bayer Pharma Aktiengesellschaft Dérivés d'oxopyridine substituée
EP3197872B1 (fr) 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft (2h)-2-oxopyridines en tant qu'inhibiteurs du facteur xia pour le traitement de maladies thrombotiques
US10414731B2 (en) 2014-09-24 2019-09-17 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
EP3197889B1 (fr) 2014-09-24 2018-08-01 Bayer Pharma Aktiengesellschaft Dérivés d'oxopyridine substitués
CN106687458B (zh) 2014-09-24 2020-10-27 拜耳制药股份公司 取代的氧代吡啶衍生物
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
EP3344618A1 (fr) 2015-09-04 2018-07-11 Bayer Pharma Aktiengesellschaft Dérivés d'oxopyridine substitués

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044031A1 (fr) * 2006-07-14 2009-04-08 Bayer HealthCare AG 2-(hétéroaryl)alkylindazole-6-phényl- et -thiénylméthylamide comme inhibiteurs de la thrombine
WO2014154794A1 (fr) * 2013-03-28 2014-10-02 Bayer Pharma Aktiengesellschaft Dérivés de l'oxopyridine substitués et, utilisation desdits dérivés dans le traitement des maladies cardiovasculaires
CN108164513A (zh) * 2013-03-28 2018-06-15 拜耳制药股份公司 取代的氧代吡啶衍生物及其在治疗心血管病症方面的用途
US20170275282A1 (en) * 2014-09-24 2017-09-28 Bayer Pharma Aktiengesellschaft Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives
US20170283412A1 (en) * 2014-09-24 2017-10-05 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
CN107428689A (zh) * 2015-03-19 2017-12-01 拜耳制药股份公司 作为治疗血栓形成的因子xia抑制剂的氧代吡啶衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
陈雅慧;刘冬;彭礼飞;: "凝血因子Ⅺ作为抗栓防治新靶点的研究进展", 中国药理学通报, no. 05, pages 619 - 622 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114560754A (zh) * 2022-02-25 2022-05-31 滁州学院 一种烷基醇的制备方法

Also Published As

Publication number Publication date
IL283990A (en) 2021-07-29
KR20210106504A (ko) 2021-08-30
MX2021007508A (es) 2021-08-05
AU2019407909A1 (en) 2021-05-27
CO2021007908A2 (es) 2021-07-19
DOP2021000128A (es) 2021-09-30
AU2019407909B2 (en) 2023-05-25
CL2021001613A1 (es) 2021-12-03
JOP20210161A1 (ar) 2023-01-30
SG11202104384PA (en) 2021-05-28
CA3124220A1 (fr) 2020-06-25
PE20211790A1 (es) 2021-09-09
EP3898633A1 (fr) 2021-10-27
ECSP21043895A (es) 2021-07-30
TW202039510A (zh) 2020-11-01
MA54521A (fr) 2022-03-30
CR20210342A (es) 2021-08-09
WO2020127504A1 (fr) 2020-06-25
JP2022514303A (ja) 2022-02-10
BR112021009435A2 (pt) 2021-08-17
EA202191764A1 (ru) 2021-10-22
AR117435A1 (es) 2021-08-04

Similar Documents

Publication Publication Date Title
CN113474348A (zh) 取代的氧代吡啶衍生物
CN115298170B (zh) 作为yap/taz-tead蛋白-蛋白相互作用抑制剂的联芳基衍生物
TWI717367B (zh) 經取代之側氧基吡啶衍生物
CN108164513B (zh) 取代的氧代吡啶衍生物及其在治疗心血管病症方面的用途
US8415378B2 (en) Isoxazol-3(2H)-one analogs as therapeutic agents
HK1210030A1 (en) Sulfamoyl-aryamides and the use thereof as medicaments for the treatment of hepatitis b
JP2020520946A (ja) デングウイルス複製阻害剤としての置換インドリン誘導体
TW201920134A (zh) 經唑取代之吡啶化合物
EP1395553B1 (fr) Derives de pyrrolidine servant d'inhibiteurs du facteur xa
CN116829545A (zh) 取代的吡唑基哌啶羧酸
CN112851570A (zh) 不饱和环胺半胱氨酸二硫衍生物制备方法及其医药用途
AU2002311451A1 (en) Pyrrolidine derivatives as factor Xa inhibitors
WO2019185046A1 (fr) Composé de lactame quaternaire et son utilisation pharmaceutique
EP1567489B1 (fr) Derives de pyrrolydin-2-one utilises comme inhibiteurs de la thrombine et du facteur xa
HK40054423A (en) Substituted oxopyridine derivatives
US20220144848A1 (en) Substituted oxopyridine derivatives
EA044932B1 (ru) Замещенные оксопиридиновые производные
CN120584119A (zh) 化合物、组合物及其使用方法
HK40078921A (en) Tricyclic compounds as egfr inhibitors
HK40012827A (en) Compounds and uses thereof
HK1063471B (en) Pyrrolidine derivatives as factor xa inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40054423

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211001

WD01 Invention patent application deemed withdrawn after publication